132 related articles for article (PubMed ID: 19438577)
1. Pemphigus-like lesions induced by imiquimod.
Bauza A; Del Pozo LJ; Saus C; Martin A
Clin Exp Dermatol; 2009 Jul; 34(5):e60-2. PubMed ID: 19438577
[TBL] [Abstract][Full Text] [Related]
2. Localized pemphigus foliaceus induced by topical imiquimod treatment.
Lin R; Ladd DJ; Powell DJ; Way BV
Arch Dermatol; 2004 Jul; 140(7):889-90. PubMed ID: 15262711
[No Abstract] [Full Text] [Related]
3. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas.
Rajan N; Langtry JA
Clin Exp Dermatol; 2006 Jan; 31(1):140-1. PubMed ID: 16309513
[No Abstract] [Full Text] [Related]
4. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
Micali G; De Pasquale R; Caltabiano R; Impallomeni R; Lacarrubba F
J Dermatolog Treat; 2002 Sep; 13(3):123-7. PubMed ID: 12227875
[TBL] [Abstract][Full Text] [Related]
6. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
Quirk C; Gebauer K; De'Ambrosis B; Slade HB; Meng TC
Cutis; 2010 Jun; 85(6):318-24. PubMed ID: 20666194
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice.
Daudén E;
J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1304-10. PubMed ID: 21348896
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
10. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
11. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
12. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
13. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Maus J; Munzel U
Eur J Dermatol; 2008; 18(6):677-82. PubMed ID: 18955210
[TBL] [Abstract][Full Text] [Related]
14. Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factor-alpha inhibition: more than a coincidental occurrence?
Saggini A; Saraceno R; Chimenti S
Int J Immunopathol Pharmacol; 2011; 24(2):509-15. PubMed ID: 21658326
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
[TBL] [Abstract][Full Text] [Related]
16. Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients.
Waalboer-Spuij R; Holterhues C; van Hattem S; Schuttelaar ML; Gaastra MT; Kuijpers DI; Hollestein LM; Nijsten TE
Dermatology; 2015; 231(1):56-62. PubMed ID: 25925162
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis induced by topical imiquimod.
Wu JK; Siller G; Strutton G
Australas J Dermatol; 2004 Feb; 45(1):47-50. PubMed ID: 14961909
[TBL] [Abstract][Full Text] [Related]
20. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream.
Micali M; Nasca MR; Musumeci ML
Int J Tissue React; 2005; 27(3):111-4. PubMed ID: 16372477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
